{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:22:26Z","timestamp":1762507346044,"version":"3.37.3"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T00:00:00Z","timestamp":1520553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>A 30\u2010year\u2010old pregnant female presented with a 2\u2010week history of pityriasis rosea\u2010like eruption. The rash started 2\u00a0days after the patient had started taking ondansetron 8\u00a0mg for alleviation of moderate\u2010to\u2010severe nausea and vomiting of pregnancy. Physical examination revealed erythematous papulosquamous lesions characterized by annular scaly margins and a dusky centre over the arms, chest, abdomen, lower back and legs. The rash did not involve the palms, sole or mucous membranes, and no lesions were observed on the lymph nodes. Ondansetron was discontinued. The rash ceased to spread and started to disappear within 2\u00a0weeks with full resolution noted after 1\u00a0month. Analysis of the case using the Naranjo adverse drug reaction probability scale indicated that ondansetron was the probable cause of the pityriasis rosea\u2010like eruption. This is the first case report of pityriasis rosea related to ondansetron therapy.<\/jats:p>","DOI":"10.1111\/bcp.13560","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T06:16:42Z","timestamp":1520576202000},"page":"1077-1080","source":"Crossref","is-referenced-by-count":12,"title":["Pityriasis rosea\u2010like eruption associated with ondansetron use in pregnancy"],"prefix":"10.1111","volume":"84","author":[{"given":"Malak M.","family":"Alame","sequence":"first","affiliation":[{"name":"School of Pharmacy Lebanese International University  Beirut Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina J.","family":"Chamsy","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine American University of Beirut Medical Center  Beirut Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3807-6409","authenticated-orcid":false,"given":"Hassan","family":"Zaraket","sequence":"additional","affiliation":[{"name":"Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine American University of Beirut Medical Center  Beirut Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,9]]},"reference":[{"volume-title":"Fitzpatrick's Dermatology in General Medicine","year":"2012","author":"Blauvelt A","key":"e_1_2_6_2_1"},{"unstructured":"StulbergDL WolfreyJ.Pityriasis rosea\u2010caring for common skin conditions.2004; Available at:http:\/\/www.drplace.com\/Pityriasis_rosea_\u2010_Caring_For_Common_Skin_Conditions.16.18815.htm(last accessed 11 September 2017).","key":"e_1_2_6_3_1"},{"doi-asserted-by":"publisher","key":"e_1_2_6_4_1","DOI":"10.1159\/000445375"},{"doi-asserted-by":"publisher","key":"e_1_2_6_5_1","DOI":"10.1016\/j.reprotox.2007.05.005"},{"volume-title":"The Color Atlas of Family Medicine","year":"2013","author":"Usatine RP","key":"e_1_2_6_6_1"},{"volume-title":"StatPearls","year":"2017","author":"Nair PA","key":"e_1_2_6_7_1"},{"doi-asserted-by":"publisher","key":"e_1_2_6_8_1","DOI":"10.1097\/01.NPR.0000511012.21714.66"},{"doi-asserted-by":"publisher","key":"e_1_2_6_9_1","DOI":"10.1016\/j.clindermatol.2016.02.005"},{"unstructured":"Ondansetron: drug information \u2010 UpToDate[Internet]. Available at:https%3A%2F%2Fwww.uptodate.com%2Fcontents%2Fondansetron-drug-information%3Fsource%3Dsearch_result%26amp%3Bsearch%3Dondansetron%26amp%3BselectedTitle%3D1~132(last accessed 12 September 2017).","key":"e_1_2_6_10_1"},{"doi-asserted-by":"publisher","key":"e_1_2_6_11_1","DOI":"10.1038\/clpt.1981.154"},{"doi-asserted-by":"publisher","key":"e_1_2_6_12_1","DOI":"10.1016\/S0140-6736(05)63203-5"},{"doi-asserted-by":"publisher","key":"e_1_2_6_13_1","DOI":"10.1046\/j.1523-1747.2002.00200.x"},{"doi-asserted-by":"publisher","key":"e_1_2_6_14_1","DOI":"10.1111\/j.0022-202X.2005.23719.x"},{"doi-asserted-by":"publisher","key":"e_1_2_6_15_1","DOI":"10.1177\/1753495X15621154"},{"doi-asserted-by":"publisher","key":"e_1_2_6_16_1","DOI":"10.1097\/AOG.0000000000001048"},{"doi-asserted-by":"publisher","key":"e_1_2_6_17_1","DOI":"10.1001\/jama.2016.14337"},{"doi-asserted-by":"publisher","key":"e_1_2_6_18_1","DOI":"10.1007\/s00737-016-0707-4"},{"doi-asserted-by":"crossref","unstructured":"Treatment of hyperemesis gravidarum with the 5\u2010HT3 antagonist ondansetron (Zofran). | Postgraduate Medical Journal [Internet]. Available at:http:\/\/pmj.bmj.com.ezproxy.aub.edu.lb\/content\/72\/853\/688.long(last accessed 27 September 2017).","key":"e_1_2_6_19_1","DOI":"10.1136\/pgmj.72.853.688"},{"doi-asserted-by":"publisher","key":"e_1_2_6_20_1","DOI":"10.1016\/j.jaip.2013.05.004"},{"doi-asserted-by":"publisher","key":"e_1_2_6_21_1","DOI":"10.1186\/1752-1947-2-274"},{"doi-asserted-by":"publisher","key":"e_1_2_6_22_1","DOI":"10.1097\/EJA.0000000000000372"},{"doi-asserted-by":"publisher","key":"e_1_2_6_23_1","DOI":"10.1159\/000018459"},{"doi-asserted-by":"publisher","key":"e_1_2_6_24_1","DOI":"10.1159\/000246564"},{"key":"e_1_2_6_25_1","first-page":"497","article-title":"A rare case of fixed drug eruption due to ondansetron","volume":"42","author":"Maitra A","year":"2017","journal-title":"Iran J Med Sci"},{"key":"e_1_2_6_26_1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1684\/ejd.2010.0980","article-title":"A three\u2010year\u2010analysis of fixed drug eruptions in hospital settings in France","volume":"20","author":"Brahimi N","year":"2010","journal-title":"Eur J Dermatol EJD"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13560","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:06:49Z","timestamp":1695546409000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,9]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/bcp.13560"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13560","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2018,3,9]]}}}